Toggle light / dark theme

Anthropic, an artificial intelligence company founded by exiles from OpenAI, has introduced the first AI model that can produce either conventional output or a controllable amount of reasoning needed to solve more grueling problems.

Anthropic says the new hybrid model, called Claude 3.7, will make it easier for users and developers to tackle problems that require a mix of instinctive output and step-by-step cogitation. The user has a lot of control over the behavior—how long it thinks, and can trade reasoning and intelligence with time and budget, says Michael Gerstenhaber, product lead, AI platform at Anthropic.

Claude 3.7 also features a new scratchpad that reveals the model’s reasoning process. A similar feature proved popular with the Chinese AI model DeepSeek. It can help a user understand how a model is working over a problem in order to modify or refine prompts.

Dianne Penn, product lead of research at Anthropic, says the scratchpad is even more helpful when combined with the ability to ratchet a model’s reasoning up and down. If, for example, the model struggles to break down a problem correctly, a user can ask it to spend more time working on it.

https://search.app/?link=https://www.youtube.com/watch?v=faI…cover/m5/4

Closer to truth aspects of consciousness.


Like Closer To Truth on Facebook and discover daily videos, updates, announcements, and more: https://shorturl.at/tak4l.

We offer distinctive approaches to consciousness, including cognitive science, phenomenology, and even the implications of aesthetics like fiction and films. We observe the richness of consciousness studies.

A large study of 18,740 dementia patients found that those taking antidepressants experienced faster cognitive decline compared to those who were not medicated.

Selective serotonin reuptake inhibitors (SSRIs), particularly escitalopram, citalopram, and sertraline, were associated with the greatest deterioration.

Mirtazapine, which works differently from SSRIs, had a milder impact on cognitive function.

While depression itself can worsen dementia symptoms, it remains unclear whether the decline is due to the medication or the underlying condition.

Researchers emphasize the need for more individualized treatment approaches to balance mental health benefits with potential cognitive risks.

A robotic arm that moves with nothing but the power of thought—a concept that once seemed like pure science fiction is now at the heart of Neuralink’s latest breakthrough. The brain-chip company, founded by Elon Musk, has unveiled an ambitious project that aims to connect its neural implant, the N1, to an experimental robotic limb, potentially transforming the lives of people with paralysis.

Scientists are hunting for axions, tiny particles that could solve major physics mysteries, including why neutrons don’t have an electric dipole moment and what dark matter is made of. Using the powerful European XFEL in Hamburg, researchers fired X-rays through special crystals, hoping to witness axions converting into light—a sign of their existence. This pioneering experiment, already competitive with major particle accelerator studies, demonstrates that XFEL technology could be a game-changer in particle physics.

LMU researchers have shown that a particular type of immune cell acts more flexibly than previously thought—with the potential for new therapeutic approaches.

As part of the innate immune system, dendritic cells are the body’s first line of defense against infections. They detect pathogens and coordinate the . An international team led by Professor Barbara Schraml from LMU’s Biomedical Center has now carried out an extensive study of a new type of dendritic cell and uncovered its important role in the body’s immune response. The study is published in the journal Proceedings of the National Academy of Sciences.

As the researchers demonstrate, dendritic cells that are marked by expression of the transcription factor RORγt—so-called RORγt+ (DCs)—are found in many tissues. Moreover, they have been conserved across many species in the course of evolution, which suggests they have essential functions.

Controlling Sepsis, ARDS And Other Life Threatening Inflammatory Diseases — Prof. Dr. Niels Riedemann, MD, Ph.D. — CEO, InflaRx


Prof. Dr. Niels Riedemann, MD, Ph.D. is Chief Executive Officer and Founder of InflaRx (https://www.inflarx.de/Home/About-Inflarx/Team~Niels-C.-Riedemann~.h… a biopharmaceutical company focused on applying its proprietary anti-C5a and C5aR inhibitors to the treatment of life-threatening or debilitating inflammatory diseases with high unmet medical need.

Prof. Dr. Riedemann has over 15 years of experience in the biotech industry and drug development, as well as over 20 years of experience in complement immunology research. He founded InflaRx in 2007 and has served as Chief Executive Officer since inception of the company. He has been instrumental in and led numerous private and public financing rounds of the company and has been the responsible lead for its Nasdaq IPO in 2017. He is named inventor on several internationally granted core patents of InflaRx.

A team led by researchers at UNC-Chapel Hill have made an extraordinary discovery that is reshaping our understanding of bubbles and their movement. Picture tiny air bubbles inside a container filled with liquid. When the container is shaken up and down, these bubbles engage in an unexpected, rhythmic “galloping” motion—bouncing like playful horses and moving horizontally, even though the shaking occurs vertically.

This counterintuitive phenomenon, revealed in a new study published in Nature, has significant implications for technology, from cleaning surfaces to improving in microchips and even advancing .

These galloping bubbles are already garnering significant attention: their impact in the field of fluid dynamics has been recognized with an award for their video entry at the most recent Gallery of Fluid Motion, organized by the American Physical Society.